NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2026)
NewAmsterdam Pharma (NAMS) reported Goodwill & Intangibles of $375000.0 for Q1 2026, down 25.3% on a YoY basis from $502000.0 in Q1 2025, and down 7.86% sequentially from $407000.0 in Q4 2025.
NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 5 years of Goodwill & Intangibles data on file, last reported at $375000.0 in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles fell 25.3% year-over-year to $375000.0; the trailing twelve-month figure through Mar 2026 stood at $375000.0 (down 25.3% YoY), and the FY2025 full-year result was $407000.0, down 23.78% from the prior year.
- Goodwill & Intangibles slipped to $375000.0 in Q1 2026, from $407000.0 in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $88.9 million in Q2 2023 to a low of $84843.8 in Q4 2022.
- A 5-year average of $7.8 million and a median of $478000.0 in 2024 frame the typical range for Goodwill & Intangibles.
- Peak annual rise in Goodwill & Intangibles reached 214.12% in 2024, while the deepest fall reached 99.39% in 2024.
- Tracing NAMS's Goodwill & Intangibles over 5 years: stood at $84843.8 in 2022, then jumped by 100.37% to $170000.0 in 2023, then soared by 214.12% to $534000.0 in 2024, then retreated by 23.78% to $407000.0 in 2025, then declined by 7.86% to $375000.0 in 2026.
- Business Quant data shows NAMS's Goodwill & Intangibles at $375000.0 in Q1 2026, $407000.0 in Q4 2025, and $439000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | 407,000.00 |
| Sep 30, 2025 | 439,000.00 |
| Jun 30, 2025 | 470,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 534,000.00 |
| Sep 30, 2024 | 593,000.00 |
| Jun 30, 2024 | 542,000.00 |
| Mar 31, 2024 | 486,000.00 |
| Dec 31, 2023 | 170,000.00 |
| Jun 30, 2023 | 88.89 Mn |
| Dec 31, 2022 | 84,843.77 |